ANTICIPATED/EXPECTED BEST SELLING PRODUCTS OF 2023
CLICK HERE TO CHECK TOP PHARMACEUTICALS BY REVENUES IN 2023
Evaluate has published the sales forecast of pharmaceuticals for 2023, and Merck's PD-L1 inhibitor, Keytruda, is expected to be the best-selling drug. The top ten list includes monoclonal antibodies, vaccines, and small molecules.
Also read: Japan drug approvals
There is uncertainty regarding the sales of COVID-19 vaccines and drugs as the requirement is decreasing. Eylea can also feature in the top 10 list if COVID-19 vaccines and drugs cannot generate more than $10 billion in revenues.
Evaluate estimated that Merck's PD-L1 inhibitor will add another $3 billion in new sales in 2023. The drug is expected to generate nearly ~$24 billion in 2023. Keytruda is approved for almost 18 cancers.
Also read: China drug approvals
Keytruda revenues are growing consistently, contributing to nearly 40% of Merck's pharmaceutical segment's revenues. By Q3 of 2022, Merck reported that Keytruda's revenue had increased by 20%.
Approval in the earlier stages of cancers, including triple-negative breast cancer, is helping the company in the US, while uptake in the NSCLC, HNSCC and advanced RCC is driving the revenue growth in the ex-US markets.
Pfizer and BioNTech's COVID-19 vaccine is expected to generate revenues under $ 20 billion in 2023. Comirnaty and Paxlovid have driven the revenues of Pfizer in 2022, with the company revenues expected to touch $100 billion. The COVID-19 vaccine and tablet together generated $56 billion in revenues in 2022, which is more than 55% of the company's revenues.
Comirnaty was the best-selling product in 2022, with Pfizer's forecasted revenues of ~$34 billion. However, with the requirements for COVID-19 vaccines and medicines decreasing, the revenues are expected to reduce significantly in 2023.
Also read: NICE assessment outcomes
AbbVie's TNF inhibitor, Humira, will face biosimilar competition in 2023 in the US and is expected to lose nearly 6.5 billion from its revenues. Biosimilars for Humira are already available in Europe.
Humira generated more than $150 billion in revenues in the last decade, with the product generating more than $10 billion since 2013. In 2021, Humira sales crossed $20 billion for the first time and continued the same revenues in 2022.
Pfizer's COVID drug i